- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.12.24 | Ikena Oncology and Inmagene Biopharmaceuticals announces merger | 6 | Seeking Alpha | ||
| 23.12.24 | Ikena Oncology, Inc.: Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement | 135 | GlobeNewswire (Europe) | Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction... ► Artikel lesen | |
| 23.12.24 | Ikena Oncology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| IKENA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 07.11.24 | Ikena Oncology, Inc.: Ikena Oncology Reports Third Quarter 2024 Financial Results | 162 | GlobeNewswire (Europe) | BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company") today announced financial results for the third quarter ended September 30, 2024, and provided an... ► Artikel lesen | |
| 07.11.24 | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.08.24 | Ikena Oncology GAAP EPS of -$0.28 | 2 | Seeking Alpha | ||
| 08.08.24 | Ikena Oncology, Inc.: Ikena Oncology Reports Second Quarter 2024 Financial Results | 136 | GlobeNewswire (Europe) | BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company") today announced financial results for the second quarter ended June 30, 2024, and provided an update... ► Artikel lesen | |
| 29.05.24 | Pre-market Movers: Cheche Group, AERWINS Technologies, Siyata Mobile, Surmodics, Ikena Oncology | 567 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheche Group Inc. (CCG) is up over 58% at $2.11.
Siyata... ► Artikel lesen | |
| 29.05.24 | Ikena Oncology, Inc. Announces Strategic Update | 223 | GlobeNewswire (Europe) | Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring... ► Artikel lesen | |
| 13.05.24 | Ikena Oncology, Inc.: Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update | 236 | GlobeNewswire (Europe) | Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and... ► Artikel lesen | |
| 12.03.24 | Ikena Oncology, Inc.: Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results | 301 | GlobeNewswire (Europe) | IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in... ► Artikel lesen | |
| 21.02.24 | Ikena Oncology, Inc.: Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer | 227 | GlobeNewswire (Europe) | Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development strategy... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 112,80 | +0,18 % | BioNTech-Aktie: Wird 2025 ein gutes Jahr? | Im vergangenen Jahr hat die BioNTech-Aktie nicht gerade mit einer starken Performance geglänzt. Worauf müssen sich Anleger 2025 einstellen? Was spricht für steigende Kurse, was dagegen? Verhaltener... ► Artikel lesen | |
| EVOTEC | 8,165 | +3,22 % | Evotec Aktie in Problemen: Bringt diese Woche die Wende? | Die Evotec-Aktie bleibt charttechnisch nach der jüngsten Abwärtsbewegung auf 7,65 Euro in einer schwierigen Lage. Nach dem Rückfall unter die Unterstützungszone bei 7,98 / 8,07 Euro in der vergangenen... ► Artikel lesen | |
| BIOFRONTERA | 2,585 | -0,19 % | Biofrontera files to sell 5.72M shares of common stock by selling shareholders | ||
| BIOGEN | 138,70 | -0,43 % | Biogen Says FDA And EMA Accept Applications For Higher Dose Regimen Of Nusinersen In SMA | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | 0,00 % | Prusa gibt Update zum 3D-Drucker CORE One: Erste Auslieferungen stehen bevor | ||
| PALATIN TECHNOLOGIES | 0,932 | +2,98 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation zur Erkennung von fortgeschrittenen Adenomen in einer großen Patientenpopulation | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,130 | +0,73 % | Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week | ||
| TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| ASEP MEDICAL | 0,033 | -11,89 % | Asep Medical wird in landesweit ausgestrahlter Dokumentarreihe präsentiert | Asep wurde für eine spezielle Dokumentarreihe mit dem Titel "Empowered, Hosted by Meg Ryan"
ausgewählt, bei der Führungspersonen aus Wissenschaft, Technologie und Medizin im Blickpunkt stehen.
... ► Artikel lesen | |
| GALAPAGOS NV | 22,660 | +0,27 % | Galapagos inks agreement with Catalent for experimental CAR-T therapy | ||
| CENTOGENE | 0,120 | +20,00 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| AFFIMED | 1,060 | +1,92 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,230 | -6,50 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| COHERUS | 1,196 | +1,61 % | Coherus BioSciences, Inc.: Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 | - Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate - - Antitumor... ► Artikel lesen |
IKENA ONCOLOGY INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,40 % bei einem Aktienkurs von 1,495 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IKENA ONCOLOGY INC finden Sie auf Wallstreet Online.
